TBPH Company Profile and Key Details

TBPH has shown sold momentum, gaining 3.92% over the past week and 43.2% over the past quarter, though year-to-date performance is up 9.14%. Short-term trend indicators are bearishly aligned (SMA20 -6.25%, SMA50 -5.5%, SMA200 23.07%). The stock’s 14-day RSI is 38.26 (weak momentum), while the ATR of 0.87 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -13.5% below its high and over 130.25% above its low. Average 10-day trading volume of 700.66 thousand shares is slightly above the 3-month average of 578.23 thousand, indicating heightened recent market interest.

Theravance Biopharma Inc has 51.83 million shares outstanding. The public float is 24.15 million shares, elevated short interest at 13.28% of float. This equals 4.31 million shares. The short ratio is 4.62 days. Institutional investors hold 103.04% of the float. Insiders own 4.68%. Samaha Eli holds 8.01 million shares, Winningham Rick E has 1.35 million shares and GRAHAM RICHARD A has 346.84 thousand shares. Over the past six months, insider transactions show net selling. They sold 14.42 thousand shares across 2 transactions.

Theravance Biopharma Inc generated EPS of $0.56 over the past year. Five-year average earnings growth is 22.95%. Wall Street analysts project EPS growth of 66.26% annually over the next five years. The latest quarter delivered EPS of -$0.10. The next quarter is forecast at $1.01. Next year's EPS is expected at $37.33. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 8 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $15.00. The high target offers 137.25% upside. The low target suggests -11.03% downside. The mean target is $26.69. This offers 58.3% upside. Theravance Biopharma Inc earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by -457.14%. The prior quarter beat by -86.36%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in February 26, 2025.

Theravance Biopharma Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $11.83. This means the shares are trading above this model’s fair value.

The stock is currently mid-range between its 52-week high and low $10.82 and $21.03. With a market capitalization of about $873.82 million, Theravance Biopharma Inc is classified as a small-cap and shows lower-than-market volatility (beta ~0.17). Key stats such as the average daily volume over the past year has been around 590.52 thousand shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, Theravance Biopharma Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Rick E. Winningham, the company employs approximately 90 people and listed since May 16, 2014. Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.

Theravance Biopharma Inc trades at a P/E ratio of 7.46, slightly below the S&P 500 average, with a price-to-sales ratio of 7.97 and a price-to-book ratio of 2.98 suggesting the stock is closer to book value. The P/FCF stands at 3.26, also above market averages.

Theravance Biopharma Inc (NASDAQ:TBPH) shares are flat 9.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Theravance Biopharma Inc trading at a premium to the broader market with a P/E of 7.46. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $25.52, suggesting 51.36% upside. Our AI forecast model points to short-term weakness (-0.77% over two weeks), a medium-term fall (-1.36% over three months), and a longer-term gain (17.79% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Theravance Biopharma Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.77%, with price expected at $16.73 by August 07, 2026, within a range of $16.52 to $16.96 3-Month Outlook: Projected fall of -1.36%, reaching $16.63 by October 22, 2026, with a range of $16.46 to $16.85. 1-Year Outlook: Projected gain of 17.79%, with price at $19.86 by July 23, 2027, within a range of $18.87 to $20.80.